The late-breaking abstract reports a pooled analysis of individual patient data from four infliximab registrational studies. (PRNewswire) - Oct 11, 2026 - "In the matched population at Week 54, patients receiving SC infliximab had higher rates of clinical remission, endoscopic response, and endoscopic remission than those receiving IV infliximab: Clinical remission: 71.4% vs. 51.4% (P = 0.023); Endoscopic response: 65.7% vs. 27.1% (P < 0.001); Endoscopic remission: 41.4% vs. 17.1% (P = 0.003); The analysis also found that, in both treatment groups, endoscopic responders had significantly higher serum infliximab concentrations than nonresponders."
Retrospective data • Crohn's disease
|